SCOPUS BIOPHARMA

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch SCPS and buy or sell other stocks, ETFs, and their options commission-free!

About SCPS

Scopus Biopharma, Inc. is a biopharmaceutical company, which engages in the development of therapeutics targeting diseases with unmet medical needs. The company was founded on April 18, 2017 and is headquartered in New York, NY. 

CEO
Morris C. Laster, MD
CEOMorris C. Laster, MD
Employees
13
Employees13
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
2017
Founded2017
Employees
13
Employees13

SCPS Key Statistics

Market cap
16.83K
Market cap16.83K
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
114.60
Average volume114.60
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$0.01
52 Week high$0.01
52 Week low
$0.0003
52 Week low$0.0003

Stock Snapshot

SCOPUS BIOPHARMA(SCPS) stock is priced at $0.00, giving the company a market capitalization of 16.83K.

SCOPUS BIOPHARMA(SCPS) stock opened on 2026-03-06 at —. The price climbed to — and dipped to —.

SCOPUS BIOPHARMA(SCPS) shares are trading with a volume of 0, against a daily average of 114.6.

In the last year, SCOPUS BIOPHARMA(SCPS) shares hit a 52-week high of $0.01 and a 52-week low of $0.00.

In the last year, SCOPUS BIOPHARMA(SCPS) shares hit a 52-week high of $0.01 and a 52-week low of $0.00.

People also own

Based on the portfolios of people who own SCPS. This list is generated using Robinhood data, and it’s not a recommendation.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.